NDAORALCAPSULEPriority Review
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRUSELTIQ (infigratinib phosphate) is an oral small-molecule fibroblast growth factor receptor (FGFR) inhibitor approved for cholangiocarcinoma and other FGFR-driven malignancies. The drug targets FGFR genetic alterations that drive tumor growth, offering a precision medicine approach to patients with FGFR2 fusions or other activating mutations.
$0.351MPart D
Peak8.6 years to LOEModest Part D utilization suggests niche market positioning in a narrow patient population; commercial teams are likely lean and specialized in precision oncology.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Work on TRUSELTIQ positions professionals within a specialized precision oncology product in the growth-to-peak phase, emphasizing niche market expertise and patient selection capabilities. The limited job postings suggest a highly focused team structure with opportunities primarily in targeted medical affairs and narrow-patient-pool commercial roles.
Company
Worked on TRUSELTIQ at Helsinn? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.